RU2122426C1 - Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина - Google Patents

Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина Download PDF

Info

Publication number
RU2122426C1
RU2122426C1 RU94045932A RU94045932A RU2122426C1 RU 2122426 C1 RU2122426 C1 RU 2122426C1 RU 94045932 A RU94045932 A RU 94045932A RU 94045932 A RU94045932 A RU 94045932A RU 2122426 C1 RU2122426 C1 RU 2122426C1
Authority
RU
Russia
Prior art keywords
histidine
growth hormone
derivative
hgh
crystals
Prior art date
Application number
RU94045932A
Other languages
English (en)
Russian (ru)
Other versions
RU94045932A (ru
Inventor
Хольмегорд Серенсен Ханс
Скривер Ларс
Рассинг Холгорд Анни
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU94045932A publication Critical patent/RU94045932A/ru
Application granted granted Critical
Publication of RU2122426C1 publication Critical patent/RU2122426C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU94045932A 1991-12-20 1992-12-16 Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина RU2122426C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK2046/91 1991-12-20
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
DK1364/92 1992-11-10

Publications (2)

Publication Number Publication Date
RU94045932A RU94045932A (ru) 1997-04-20
RU2122426C1 true RU2122426C1 (ru) 1998-11-27

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045932A RU2122426C1 (ru) 1991-12-20 1992-12-16 Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина

Country Status (24)

Country Link
EP (2) EP1197222B1 (fr)
JP (2) JP2950617B2 (fr)
KR (1) KR100266502B1 (fr)
AT (2) ATE227583T1 (fr)
AU (1) AU667503B2 (fr)
BG (1) BG63075B1 (fr)
CA (1) CA2125855C (fr)
CZ (1) CZ283361B6 (fr)
DE (3) DE69232847T2 (fr)
DK (1) DK0618807T3 (fr)
ES (2) ES2291264T3 (fr)
FI (1) FI115116B (fr)
HU (1) HUT69402A (fr)
IL (1) IL104152A (fr)
MX (1) MX9207374A (fr)
NL (1) NL300126I1 (fr)
NO (1) NO942300L (fr)
NZ (1) NZ246556A (fr)
PT (1) PT618807E (fr)
RO (1) RO111990B1 (fr)
RU (1) RU2122426C1 (fr)
SK (1) SK279641B6 (fr)
UA (1) UA41502C2 (fr)
WO (1) WO1993012812A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592671C2 (ru) * 2010-09-21 2016-07-27 Ферринг Б.В. Улучшенный способ получения рекомбинантного человеческого гормона роста
RU2803237C2 (ru) * 2018-10-26 2023-09-11 Ново Нордиск А/С Стабильные композиции на основе семаглутида и их варианты применения

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
WO1995035116A1 (fr) * 1994-06-17 1995-12-28 Applied Research Systems Compositions pharmaceutiques renfermant l'hch
IL114030A (en) * 1994-06-27 2000-08-13 Hayashibara Biochem Lab Saccharide composition with a lesser reducibility its preparation and compositions containing it
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
JPH10511964A (ja) * 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
EP2311436A1 (fr) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Cristaux de protéines stabilisées, formulations renfermant lesdits cristaux et leurs procèdes de fabrication
KR20090007504A (ko) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
MXPA03000073A (es) 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
CA2418960A1 (fr) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
NZ528260A (en) 2001-05-18 2005-09-30 Danisco Method of improving dough and bread quality with the addition of an enzyme that hydrolyses a glycolipid and a phospholipid and incapable of hydrolysing a triglyceride or monoglyceride
BR0317888A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
EP1660531A2 (fr) 2003-08-05 2006-05-31 Novo Nordisk A/S Nouveaux derives de l'insuline
ATE514767T1 (de) 2004-07-16 2011-07-15 Danisco Enzymatisches öldegummierungsverfahren
PL1827483T3 (pl) * 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Formulacje terapeutyczne czynnika wzrostu keratynocytów
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
KR20080038391A (ko) * 2005-08-30 2008-05-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페그화 성장 호르몬의 액체 제제
WO2007033427A1 (fr) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation de peptides comprenant des acides aminés basiques
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CA2738615A1 (fr) 2008-10-30 2010-05-06 Novo Nordisk A/S Traitement du diabete a l'aide d'injections d'insuline avec une frequence inferieure a une injection par jour
PL2465542T3 (pl) * 2008-12-16 2015-06-30 Genzyme Corp Koniugaty białko-oligosacharyd
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR102429287B1 (ko) * 2015-12-10 2022-08-05 가부시끼가이샤 메니콘 펩티드 조성물
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
SG11202011353XA (en) * 2018-05-25 2020-12-30 Dr Reddys Laboratories Ltd Stable fusion protein formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CA3116271A1 (fr) 2018-10-26 2020-04-30 Novo Nordisk A/S Compositions de semaglutide stables et leurs utilisations
WO2022197963A1 (fr) * 2021-03-19 2022-09-22 Pfizer Inc. Compositions d'hormone de croissance à action prolongée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0374120A3 (fr) * 1988-12-13 1991-07-31 Monsanto Company Composition pour la libération contrôlée des polypeptides
DK168790D0 (fr) * 1990-07-13 1990-07-13 Novo Nordisk As

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592671C2 (ru) * 2010-09-21 2016-07-27 Ферринг Б.В. Улучшенный способ получения рекомбинантного человеческого гормона роста
RU2803237C2 (ru) * 2018-10-26 2023-09-11 Ново Нордиск А/С Стабильные композиции на основе семаглутида и их варианты применения

Also Published As

Publication number Publication date
JP2950617B2 (ja) 1999-09-20
NL300126I1 (nl) 2003-07-01
JPH07502516A (ja) 1995-03-16
DE69233704D1 (de) 2007-09-13
KR100266502B1 (ko) 2000-09-15
NZ246556A (en) 1996-03-26
EP0618807B1 (fr) 2002-11-13
MX9207374A (es) 1993-07-01
HUT69402A (en) 1995-09-28
AU3344693A (en) 1993-07-28
SK279641B6 (sk) 1999-01-11
ATE227583T1 (de) 2002-11-15
PT618807E (pt) 2003-03-31
WO1993012812A1 (fr) 1993-07-08
DE10399015I2 (de) 2008-08-07
DE10399015I1 (de) 2012-05-03
HU9401832D0 (en) 1994-09-28
IL104152A (en) 1998-06-15
RU94045932A (ru) 1997-04-20
AU667503B2 (en) 1996-03-28
NO942300L (no) 1994-08-19
NO942300D0 (no) 1994-06-17
DE69232847T2 (de) 2003-09-11
FI942906A (fi) 1994-06-17
ES2291264T3 (es) 2008-03-01
DE69233704T2 (de) 2008-05-21
CZ283361B6 (cs) 1998-03-18
ATE368472T1 (de) 2007-08-15
BG63075B1 (bg) 2001-03-30
IL104152A0 (en) 1993-05-13
EP0618807A1 (fr) 1994-10-12
FI942906A0 (fi) 1994-06-17
CA2125855C (fr) 2008-05-13
SK75494A3 (en) 1995-03-08
DE69232847D1 (de) 2002-12-19
JPH11315031A (ja) 1999-11-16
RO111990B1 (ro) 1997-04-30
EP1197222B1 (fr) 2007-08-01
CZ150794A3 (en) 1995-01-18
CA2125855A1 (fr) 1993-07-08
UA41502C2 (uk) 2001-09-17
DK0618807T3 (da) 2003-03-03
FI115116B (fi) 2005-03-15
ES2185625T3 (es) 2003-05-01
EP1197222A2 (fr) 2002-04-17
EP1197222A3 (fr) 2004-02-04
BG98806A (bg) 1995-02-28

Similar Documents

Publication Publication Date Title
RU2122426C1 (ru) Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина
US5849700A (en) Pharmaceutical formulation
US5849704A (en) Pharmaceutical formulation
CA2252535C (fr) Formulation pharmaceutique contenant une hormone de croissance, un acide amine et un detergent non ionique
RU2098130C1 (ru) Фармацевтический препарат гормона роста и его стабилизатор
US5705482A (en) Pharmaceutical formulation
CA2226523A1 (fr) Formulation pharmaceutique stabilisee comprenant une hormone de croissance pre-traitee avec des ions zinc et facultativement lysine ou calcium
US8841252B2 (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
JP4064454B2 (ja) 成長ホルモンおよびイソロイシンを含んでなる医薬製剤
JP4064453B2 (ja) 成長ホルモンおよびバリンを含んでなる医薬製剤
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
EP0785797B1 (fr) Formulation pharmaceutique comportant une hormone de croissance et de la leucine
PL171356B1 (pl) Sposób wytwarzania kryształów hormonu wzrostu lub pochodnych hormonu wzrostu i histydyny lub pochodnej histydyny
MXPA98008786A (en) A pharmaceutical formulation containing a growth hormone, an amino acid and a non-ion detergent

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20111220